N-Acetyl Selank Amidate
Longer-acting Selank variant · evidence borrowed from plain Selank · intranasal
N-Acetyl Selank Amidate is a chemically modified, claimed-longer-acting version of Selank — a Russian anti-anxiety peptide based on tuftsin, a small natural immune-signaling molecule. Two protective caps (an acetyl group on one end, an amide on the other) are added to slow the enzymes that break the peptide down. The honest core of this page is that the variant has no published research of its own: there is not a single dedicated clinical or preclinical study of the acetyl-amidate itself. Everything attributed to it is borrowed from plain Selank, whose own evidence is a small, short, almost entirely Russian-conducted body of work that Western researchers have rarely replicated — its two main human trials had 62 and 70 patients. The 'more stable, more bioavailable' claim is a reasonable chemistry argument but has never been demonstrated head-to-head for this molecule. There is also a real identifier problem: vendors routinely paste plain Selank's chemical ID, formula, and weight onto the amidate, which is chemically impossible, and no verified PubChem entry for the true acetyl-plus-amidated molecule could be found — so its exact formula, molecular weight, and CAS number are unverified here rather than guessed. Plain Selank is approved only in Russia (never by the FDA or EMA); this variant is approved nowhere.
The short version
Selank is a short synthetic peptide built on tuftsin — a natural four-amino-acid fragment with immune and brain-signaling activity — extended with a small stabilizing tail so it survives longer in the body. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is used in Russia as an anti-anxiety (anxiolytic) drug that, unlike benzodiazepines, is not sedating and is not reported to cause dependence. It is given as a nasal spray and is not approved by the US FDA or the European EMA.
N-Acetyl Selank Amidate is a modified version of that peptide, with two chemical caps added — an acetyl group at one end and an amide at the other — to slow the enzymes that would otherwise break it down quickly. The intended result is a longer-acting molecule. That chemical logic is reasonable in principle.
Here is the essential caveat. This acetyl-amidate variant has no published studies of its own — not one dedicated clinical or animal study of this exact molecule. Every benefit attributed to it is borrowed from plain Selank. And plain Selank's evidence is itself limited: a small, short, almost entirely Russian set of trials and animal studies that have rarely been repeated by independent Western researchers. The two main human trials enrolled 62 and 70 patients.
There is also a chemistry-honesty problem worth flagging. Sellers frequently list plain Selank's chemical ID, formula, and molecular weight on the amidate product — which is impossible, because adding those two caps necessarily changes the formula and weight. And there is no verified database entry for the true acetyl-plus-amidated molecule. So on this page its exact formula, weight, and registry number are marked unverified rather than guessed. The only chemically sensible reading of the name is plain Selank's backbone with an acetyl and an amide cap.
Molecular identity
Specs
- Molecular weight
- ≈792.9 g/mol (calculated for Ac-TKPRPGP-NH₂; plain Selank's 751.9 g/mol does NOT apply)Calculated from acetyl-only CID 133082488 + C-amidation (not registry-verified)
- Molecular formula
- C₃₅H₆₀N₁₂O₉ (calculated; acetyl + C-amide on Selank C₃₃H₅₇N₁₁O₉ — do NOT use plain Selank's formula)Calculated from acetyl-only CID 133082488 (C₃₅H₅₉N₁₁O₁₀) + amidation; no name-matched PubChem CID
- Monoisotopic mass
- ≈792.46 Da (calculated, not registry-verified)Calculated from acetyl-only CID 133082488 + C-amidation
- Sequence (backbone)
- Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ (acetyl + amide caps on Selank TKPRPGP) — 7 AASelank backbone verified (PMID 18661785); caps are the variant claim
- Structure / class
- N-acetylated, C-amidated analog of Selank (tuftsin-derived heptapeptide); end-capped for enzymatic stabilityPlain Selank literature (modification is the vendor rationale)
- Base peptide
- Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) — tuftsin (TKPR) + Pro-Gly-ProPMID 18661785 (sequence inline); PubChem CID 11765600 (plain Selank)
- PubChem CID
- None verified for the full amidate; CID 133082488 is the acetyl-ONLY form (C₃₅H₅₉N₁₁O₁₀, MW 793.9), not C-amidatedPubChem (acetyl-only + salt entries exist; amidate not name-matched)
- CAS / UNII
- Unverified — no confirmed CAS or UNII for the amidate (vendor-listed CAS numbers are plain Selank's)No cross-confirmed registry entry for the amidate
- Water solubility
- Water-soluble; highly hydrophilic (parent Selank computed XLogP −6.1)PubChem CID 11765600 (parent, computed)
- Molecular target
- Assumed identical to Selank — enkephalinase inhibition (human serum) + rodent BDNF/GABAergic-gene effects; no amidate-specific target study existsPMID 11443939 (plain Selank, human serum); borrowed, not amidate-verified
- Half-life
- Not established — no published pharmacokinetics for the amidate; the 'longer-acting' claim is a chemistry rationale (end-capping), not a measured valueNot established
- Regulatory status
- Research chemical, approved nowhere (plain Selank: Russia-only)Regulatory absence (no FDA/EMA approval)
Plain English
Mechanism
All of the mechanism here belongs to plain Selank; the amidate is assumed to share it because it shares the backbone — assumed, not separately shown. Selank is an analog of tuftsin (the Thr-Lys-Pro-Arg motif), a peptide with immunomodulatory and neuroactive properties, and its effects are thought to flow from several overlapping actions rather than a single receptor.
One well-documented action is inhibition of the enzymes that degrade enkephalins (the body's own opioid-like regulatory peptides) — in the human anxiety trial, researchers even tracked the half-life of a leu-enkephalin marker in serum as a readout. Selank also raises BDNF (brain-derived neurotrophic factor) in animal brain tissue, and it modulates the expression of GABA-system genes: dosing changed the activity of roughly 22 genes involved in GABA signaling within a few hours, producing a benzodiazepine-like profile but, importantly, without directly binding the GABA-A receptor. It has also been reported to shift serotonin, dopamine, and norepinephrine metabolism in a region-specific way.
Two honesty points: this mechanism is predominantly animal and in-vitro work (with one human enzyme biomarker), and no mechanistic study has been done on the acetyl-amidate specifically. The 'no direct GABA-A binding' detail is part of why Selank is described as non-sedating and non-dependence-forming — but that characterization, like the rest, comes from plain Selank, not from this variant.
Why people reach for it
Potential benefits
N-Acetyl Selank Amidate is the longer-acting take on Selank — the calm end of the Russian nootropic tradition. Here's what draws people to it (all borrowed from plain Selank).
- Calm focus without drowsiness — Its headline appeal, inherited from Selank: a benzodiazepine-like calming profile that, in Selank's human trial, matched a benzo's anxiety relief while staying non-sedating — calm that doesn't dull you.
- Longer-lasting calm, fewer doses — Its defining selling point: two chemical caps slow the enzymes that break Selank down, so the chemically-plausible claim is a longer anxiolytic window from fewer daily administrations — though it has been measured for neither this molecule's duration nor potency.
- Take-the-edge-off for a demanding moment — Like Selank, it is reached for situationally before a high-stakes moment — a presentation, an exam — because the calm comes without sedation; people use a single daytime dose to steady a stressful window.
- Eases an anxious, racing mind — Selank's mechanism (which this variant is assumed to share) slows the breakdown of the body's own calming enkephalins and shifts GABA-system genes — a benzo-like profile without directly binding the GABA-A receptor — the basis for the quieter-mind effect people pursue.
- The calm partner to a focus peptide — Pairs cleanly with NA-Semax-Amidate or Semax — this variant supplies the calm, Semax the drive, the Russian focus-plus-calm combination in its longer-acting form.
Sources:PMID 18454096PMID 26356395PMID 31625062PMID 26924987
What people reach for N-Acetyl Selank Amidate for — borrowed almost entirely from plain Selank (one small Russian human trial; brain mechanism from rodents), framed by how it's used, not proven outcomes or medical claims.
Implied timing
Best time to dose
Implied best time
Daytime
Most people take N-Acetyl Selank Amidate during the day — a potent, longer-acting Selank for calm focus through the waking hours.
- Like Selank, it is non-sedating — the calm comes without drowsiness — so it is used during waking hours for daytime composure, not as a sleep aid the way a sedative would be.
- Because it is reported to act fast and not sedate, a single daytime dose ahead of a stressful or high-stakes moment is a common situational pattern, on top of (or instead of) a fixed daily schedule.
- The longer-acting chemistry means one morning dose is expected to cover much of the day; if split, morning plus early afternoon is the usual placement, and anyone sensitive to its mild cognitive activation keeps it clear of late evening.
- No pharmacokinetics have been measured for the amidate — the 'longer-acting' claim is a chemical rationale, not a value — so the daytime placement is reasoned from Selank's non-sedating anxiolytic profile and how it's used, not from a published duration.
No study establishes an ideal time of day for N-Acetyl Selank Amidate — this is reasoned from its non-sedating anxiolytic (Selank-borrowed) mechanism and how it's used. As a rule of thumb most peptide dosing lands in the midday-to-evening window; for this one the lean is the daytime side of that, and it can also be used situationally.
Sources:PMID 18454096PMID 26356395
How to run it
Dosing & protocol
N-Acetyl Selank Amidate is an intranasal-primary peptide — nasal drops or spray are the primary route, borrowing directly from plain Selank's Russian clinical practice and offering some nose-to-brain delivery. Subcutaneous injection is the secondary route used in the research-chemical community, particularly for systemic anxiolytic use. Every figure here is Selank-derived and applied to the amidate by extrapolation — no amidate-specific dosing study exists.
Evidence borrowed from plain Selank (PMID 18454096, PMID 26356395) — small, short, almost exclusively Russian trials. The amidate's own pharmacokinetics are unmeasured; the 'longer-acting' claim is a chemical rationale, not a trial finding. Every number below is community and practitioner convention, not a validated dose.
Tiered dose ranges
Intranasal and subcutaneous doses differ; start at the low end of either route to gauge sensitivity.
- Intranasal — low / first use:
- 250 mcg/day (1–2 drops or sprays per nostril, once daily) — the entry dose; gives a read on individual sensitivity before stepping up.
- Intranasal — standard:
- 300–500 mcg/day, often split morning and early afternoon across both nostrils — the range most community users settle on for ongoing anxiolytic and cognitive-calm goals.
- Subcutaneous — standard:
- 250–500 mcg once daily, drawn on a U-100 insulin syringe from the reconstituted vial (see the reconstitution card). Subcutaneous use is more consistent in delivery than drops but bypasses the nose-to-brain route.
Administration — intranasal + subcutaneous
Two routes, two techniques. Intranasal is primary (Russian clinical standard, nose-to-brain); subcutaneous is the injectable alternative.
- Intranasal — drops or spray:
- Tilt the head back slightly, deliver drops or one spray per nostril, then hold the head back for 20–30 seconds to let the fluid contact the olfactory epithelium high in the nasal cavity. Split the daily dose between nostrils — e.g. 250 mcg/nostril for a 500 mcg total dose. Plain Selank's clinical route; the nose-to-brain pathway is the primary rationale for this family of peptides.
- Subcutaneous — site and rotation:
- Inject into subcutaneous fat: abdomen (a few centimetres from the navel), outer thigh, or love-handle area. Rotate sites between doses to prevent local irritation and lipohypertrophy.
- Subcutaneous — measuring the dose:
- From a standard 10 mg vial reconstituted with 2 mL bacteriostatic water (5,000 mcg/mL): 250 mcg = 5 IU · 300 mcg = 6 IU · 500 mcg = 10 IU on a U-100 syringe. The calculator handles any vial size.
- Time of day:
- Daytime for either route — see Best time to dose above. Aligns with the anxiolytic goal during waking hours and avoids any mild stimulant-adjacent effect interfering with sleep; the non-sedating profile also suits situational use before a demanding task. For a split intranasal dose, space the two administrations 4–6 hours apart.
- Food window:
- Neither route competes meaningfully with food for absorption; administer independent of meals.
Cycle & washout
Plain Selank's Russian clinical trials ran 2–3-week courses; community use follows the same cyclical pattern.
- Standard cycle:
- 2–4 weeks of daily use, then a break. The human trials ran approximately 2–3 weeks; the community typically extends to 4 weeks before reassessing.
- Washout:
- 1–2 weeks off between cycles. Because the amidate's pharmacokinetics are unmeasured, the 'longer-acting' assumption does not reliably extend the washout — err on the same break length as plain Selank.
- On-demand use:
- Some users run a single morning dose before high-stakes situations (presentation, exam, social event) rather than a fixed course — consistent with the community's 'situational anxiolytic' pattern.
Reconstitution at a glance
Mixing math only — the calculator does this live for any vial size.
- Mixing:
- 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg/mL. On a U-100 insulin syringe: 250 mcg = 5 IU · 300 mcg = 6 IU · 400 mcg = 8 IU · 500 mcg = 10 IU.
- Intranasal solution:
- For drops: the reconstituted vial is used directly in a sterile nasal dropper bottle. For spray: transfer to a nasal atomiser (e.g. LMA MAD Nasal). Typical intranasal volumes are 0.05–0.1 mL per nostril per administration.
Sources:PMID 18454096PMID 26356395
Substrate the signal needs
Nutritional cofactor precision
The cofactor logic here is borrowed directly from plain Selank's mechanism — GABA-gene modulation, serotonin/enkephalin tone, and BDNF signalling — because the amidate has no separate biology to reason from. Reasoned first-principles from the base molecule's (mostly animal) evidence; not a cofactor study of either Selank or this variant.
Cofactor logic carried from plain Selank — borrowed evidence, labeled. No cofactor study of the amidate exists. Supplement doses are common community ranges derived from the mechanism, not amidate-specific findings.
Supply the serotonergic arm (tryptophan · 5-HTP · B6/P5P)
Selank's calming profile runs partly through serotonin; supplying the raw material keeps that arm intact.
- L-tryptophan:
- 500–1,000 mg in the evening — the dietary amino acid serotonin is synthesised from; taken at night to ride the natural serotonin-to-melatonin window without interfering with daytime focus.
- 5-HTP (alternative):
- 100–200 mg in the evening — one step closer to serotonin than tryptophan; use one or the other, not both.
- Vitamin B6 (P5P form):
- 25–50 mg with meals — the essential cofactor for both the tryptophan-to-serotonin conversion and GABA synthesis; P5P (pyridoxal-5-phosphate) is the active, directly usable form.
- Why:
- Selank modulates serotonin and enkephalin metabolism (evidence from the GABAergic-gene and animal studies); giving the serotonin pathway adequate substrate and its rate-limiting cofactor keeps the signalling the peptide nudges from being nutrient-bottlenecked.
Amplify the GABA-calming tone (magnesium glycinate · L-theanine)
Selank shifts expression of ~22 GABA-system genes; these two amplify the same calming signal from the nutritional side.
- Magnesium glycinate:
- 300–400 mg in the evening — magnesium is a physiological NMDA-glutamate antagonist (reduces excitatory tone) and a common everyday insufficiency; the glycinate form is well-tolerated at these doses.
- L-theanine:
- 100–200 mg with the morning intranasal or subcutaneous dose — the green-tea amino acid that promotes alpha-wave calmness without sedation; pairs cleanly with the anxiolytic profile without dulling cognitive sharpness.
- Why:
- Selank's benzo-like GABA-gene profile (no direct GABA-A binding) creates calm without sedation; magnesium and theanine push the same calming-vs-excitatory balance from the nutrition side — three levers on one direction rather than the same lever twice.
Support BDNF (exercise · sleep)
Selank raises BDNF in rodent brain; the two most reliable human BDNF inputs are lifestyle, not supplements.
- Aerobic exercise:
- 30+ minutes of moderate-intensity cardio, most days — the most robustly documented everyday BDNF stimulus in humans; timing is flexible relative to dosing.
- Sleep quality:
- 7–9 hours; BDNF consolidation and synaptic pruning occur during slow-wave sleep — the anecdotal anti-anxiety + sleep-quality observation from Selank users is consistent with this axis.
- Why:
- Selank's BDNF upregulation is animal data only (PMID 31625062 — plain Selank, rats), but the rationale is mechanistically coherent: a peptide that raises BDNF pairs with lifestyle inputs that do the same. No supplement replaces exercise or sleep for this arm.
Combinations + timing
Stacking notes + timing windows
NA-Selank-Amidate is the calming, anxiolytic half of its family. The best stacks bring a complementary lever — focus/drive — rather than doubling down on the same calming signal. Note: base Selank is the parent molecule, not a stack partner; stacking two Selank variants would be redundant.
User combinations reasoned from complementary mechanisms — not studied head-to-head. The amidate's own pharmacokinetics are unmeasured, so even timing assumptions are extrapolated. Convention borrowed from the Selank + Semax Russian-lineage pairing; community practice, not trial.
NA-Selank-Amidate + NA-Semax-Amidate
The definitive amidate-generation pair: calm + drive, two ends of the Russian nootropic axis in their longer-acting forms.
- Why it works:
- NA-Semax-Amidate is the focus-and-drive complement — ACTH-derived, reported to raise BDNF and sharpen cognitive output; NA-Selank-Amidate is the anxiolytic base that keeps the drive from tipping into stress or jitteriness. Two distinct levers: excitation-modulated focus vs. GABA-serotonin calm. The pairing was originated with plain Selank + Semax by the same Russian group and translated by the community into the more stable amidate forms.
- The protocol — intranasal:
- NA-Selank-Amidate 300–500 mcg intranasally in the morning (primary route); NA-Semax-Amidate 100–300 mcg intranasally alongside or 30–60 minutes later. Split across nostrils or administer sequentially. This is the most commonly reported pairing in the community.
- The protocol — subcutaneous alternative:
- NA-Selank-Amidate 300–500 mcg subcutaneously + NA-Semax-Amidate 100–300 mcg subcutaneously, co-administered or at separate sites, once in the morning. Rotate injection sites across the week.
- Outcome:
- The combination users reach for on calm-focus, low-anxiety productivity, and general anxiolytic-nootropic goals. The two peptides balance each other: Semax's stimulant edge is blunted by Selank's calming tone, and Selank's potential drowsiness risk is offset by Semax's wakefulness.
NA-Selank-Amidate + Semax
The same calm + drive logic using base Semax — more established evidence on the Semax side, same complementary mechanism.
- Why it works:
- Base Semax carries the most studied version of the ACTH-analog focus signal (PMID evidence exists for Semax in cognitive and neuroprotection contexts, Russian-conducted). Pairing it with NA-Selank-Amidate's calming arm gives the same Selank+Semax complementarity with slightly more grounded data on the stimulant partner. Different lever from NA-Selank-Amidate in every mechanistic respect.
- The protocol — intranasal:
- NA-Selank-Amidate 300–500 mcg intranasally + base Semax 200–600 mcg intranasally, both in the morning. Standard Semax intranasal doses run 200–600 mcg/day; adjust to the lower end when combining to gauge the interaction.
- The protocol — subcutaneous alternative:
- NA-Selank-Amidate 300–500 mcg subcutaneously + Semax 200–400 mcg subcutaneously, once daily in the morning, separate or adjacent sites rotated across the week.
- Outcome:
- Reached for on the same calm-focus axis as the amidate pair, but with slightly more research depth on the Semax side. Choice between Semax and NA-Semax-Amidate is often a stability and half-life preference, not an efficacy difference proven in any trial.
Reconstitution math
Reconstitution calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
6
Draw to this mark on a U-100 syringe
- Volume per dose
- 0.06 mL
- Doses per vial
- 33
- Concentration
- 5 mg/mL
One vial lasts
- Daily
- 33 days
- Every other day
- 66 days
- 5×/week
- 46 days
Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.
From the studies
Side effects from research
Plain Selank is consistently described as well tolerated in Russian clinical use, with mild and infrequent effects such as transient nasal irritation or occasional headache or dizziness, and — importantly — no reported dependence or withdrawal, which is its key advantage over benzodiazepines. One trial specifically found that adding Selank reduced a benzodiazepine's side effects.
The honest caveat is the evidence base behind that reassuring picture: it rests on small, short (about a month or less), Russian clinical studies. There is no Western-standard toxicology dossier and no long-term Western safety data. 'No noted side effects' in Russian prescribing information is not the same as a modern Western safety package.
For the amidate specifically, there is no dedicated safety study — its safety is assumed by analogy to plain Selank, which is an assumption rather than a finding. Long-term and high-dose safety of this variant is unknown.
Sources:PMID 26356395PMID 18454096
As reported in literature
Research dosing ranges
These are the studies that exist — and they are all plain Selank, mostly Russian, with no dedicated study of the acetyl-amidate variant at all. The rows separate what was actually measured (plain Selank, in humans and animals) from the amidate, whose dosing is borrowed. All clinical use is intranasal; the animal studies used injection at the doses noted.
| Dose | Route | Model | Outcome | Sources: |
|---|---|---|---|---|
| Course over ~2–3 weeks | Intranasal | Human RCT — generalized anxiety / neurasthenia, plain Selank (n=62 vs medazepam) | Anxiolysis similar to the benzodiazepine medazepam, plus an additional anti-asthenic / mild stimulant effect — small Russian-language trial | PMID 18454096 |
| Add-on course | Intranasal | Human RCT — anxiety disorders, Selank added to phenazepam (n=70) | Faster onset and fewer benzodiazepine side-effects (less sedation/memory impairment) when Selank was added — small Russian trial | PMID 26356395 |
| 0.3 mg/kg ×7d | IP (rat) | Rats — ethanol-induced memory impairment, plain Selank | Prevented the memory deficit and normalized hippocampal/cortical BDNF — ANIMAL data | PMID 31625062 |
| 0.3 mg/kg | IP (rat) | Rats — naloxone-precipitated morphine withdrawal, plain Selank | Withdrawal index reduced ~39.6% (vs ~49.3% for diazepam); attenuated convulsions and ptosis — ANIMAL data | PMID 36322304 |
| Selank-style regimen (vendor) | Intranasal | N-Acetyl Selank Amidate — research-chemical practice | Vendor protocols reuse Selank dosing; NO amidate-specific study exists, and the 'longer-acting' rationale is unverified by data | PMID 18661785 |
Quick answers
Frequently asked
How is this different from regular Selank?
It is plain Selank with two chemical caps added — an acetyl group at one end and an amide at the other — to slow the enzymes that break it down, with the goal of a longer-acting molecule. The peptide backbone and the claimed effects are otherwise the same as Selank.
Are there studies on the amidate specifically?
No. There is not a single dedicated clinical or preclinical study of the acetyl-amidate variant itself. Everything attributed to it is borrowed from plain Selank research.
Why doesn't this page list a formula or molecular weight?
Because no verified database entry exists for the true acetyl-plus-amidated molecule, and the numbers vendors usually list are actually plain Selank's — which is chemically impossible for the modified compound. Rather than guess, this page marks the amidate's formula, weight, and registry number as unverified.
Is Selank addictive or sedating?
Plain Selank is reported to be non-sedating and not to cause dependence or withdrawal, which is its main advantage over benzodiazepines — it modulates GABA-system genes without directly binding the GABA-A receptor. This characterization comes from plain Selank's Russian studies, not from dedicated testing of the amidate.
Is Selank FDA-approved?
No. Plain Selank is registered as a drug only in Russia for anxiety and asthenic conditions; it is not approved by the US FDA or the European EMA. The N-acetyl amidate variant is a research chemical approved nowhere as a distinct drug.
Is it banned in sport?
It is not named on the 2026 WADA Prohibited List, but as a substance not approved by any major health authority it most likely falls under the S0 'non-approved substances' category by inference. Treat it as prohibited and confirm with an anti-doping authority before any competitive use.
Primary sources
References
- PMID 18454096Zozulia et al., Zh Nevrol Psikhiatr 2008 — peptide anxiolytic Selank in generalized anxiety / neurasthenia (human, n=62 vs medazepam) — PLAIN SELANK
- PMID 26356395Medvedev et al., Zh Nevrol Psikhiatr 2015 — Selank add-on to phenazepam for anxiety disorders (human, n=70) — PLAIN SELANK
- PMID 31625062Kolik et al., Bull Exp Biol Med 2019 — Selank protects against ethanol-induced memory impairment via BDNF (rats) — PLAIN SELANK
- PMID 36322304Konstantinopolsky et al., Bull Exp Biol Med 2022 — Selank attenuates morphine-withdrawal signs (rats) — PLAIN SELANK
- PMID 18661785Sarkisova et al., Zh Vyssh Nerv Deiat 2008 — Selank effects on depression-like behavior (rats/mice); confirms sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro — PLAIN SELANK
- PMID 26924987Volkova et al., 2016 (PMC4757669) — Selank alters expression of GABAergic-neurotransmission genes (benzo-like profile, no direct GABA-A binding) — PLAIN SELANK
- PubChem CID 11765600PubChem Compound — Selank, CID 11765600 (C33H57N11O9, MW 751.9; PLAIN SELANK only — these numbers do NOT apply to the amidate)
- WADA 2026WADA 2026 Prohibited List — S0 (non-approved substances); Selank/amidate not named (status by inference)
Research use only · Not medical advice · Updated 2026-06-01